Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Irritable Bowel Syndrome

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    October 2017
  1. SCHUMANN D, Langhorst J, Dobos G, Cramer H, et al
    Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Oct 27. doi: 10.1111/apt.14400.
    PubMed     Text format     Abstract available


  2. BLACK CJ, Ford AC
    Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation?
    Aliment Pharmacol Ther. 2017;46:697.
    PubMed     Text format    


  3. POLSTER A, Van Oudenhove L, Jones M, Ohman L, et al
    Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:698-699.
    PubMed     Text format    


    September 2017
  4. BECKERS AB, Weerts ZZRM, Helyes Z, Masclee AAM, et al
    Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Sep 8. doi: 10.1111/apt.14294.
    PubMed     Text format     Abstract available


    August 2017
  5. KROGSGAARD LR, Lyngesen M, Bytzer P
    Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:386-387.
    PubMed     Text format    


  6. GIBSON PR, Halmos EP, Muir JG
    Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right.
    Aliment Pharmacol Ther. 2017;46:385-386.
    PubMed     Text format    


    July 2017
  7. VIJAYVARGIYA P, Camilleri M, Carlson P, Lueke A, et al
    Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.
    Aliment Pharmacol Ther. 2017 Jul 10. doi: 10.1111/apt.14214.
    PubMed     Text format     Abstract available


  8. POLSTER A, Van Oudenhove L, Jones M, Ohman L, et al
    Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms.
    Aliment Pharmacol Ther. 2017 Jul 3. doi: 10.1111/apt.14207.
    PubMed     Text format     Abstract available


    May 2017
  9. QUIGLEY EM
    Editorial: diet, inflammation and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:1278-1279.
    PubMed     Text format    


    April 2017
  10. KROGSGAARD LR, Lyngesen M, Bytzer P
    Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Apr 25. doi: 10.1111/apt.14065.
    PubMed     Text format     Abstract available


  11. WHITEHEAD WE, Duffy K, Sharpe J, Nabata T, et al
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1005.
    PubMed     Text format    


  12. NEE J, Lembo A
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2017;45:1004-1005.
    PubMed     Text format    


  13. STAUDACHER HM, Cox SR
    Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome?
    Aliment Pharmacol Ther. 2017;45:1005-1006.
    PubMed     Text format    


    March 2017
  14. CHEY WD, Dove LS, Andrae DA, Covington PS, et al
    Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14031.
    PubMed     Text format     Abstract available


    February 2017
  15. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Text format     Abstract available


  16. CREMON C, Stanghellini V, Barbaro MR, Cogliandro RF, et al
    Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Feb 6. doi: 10.1111/apt.13958.
    PubMed     Text format     Abstract available


  17. XU XJ, Yao SK
    Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:568-569.
    PubMed     Text format    


  18. BENNET SM, Tornblom H
    Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:567-568.
    PubMed     Text format    


  19. SOOD R, Ford AC
    Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?
    Aliment Pharmacol Ther. 2017;45:563-564.
    PubMed     Text format    


    January 2017
  20. SOOD R, Gracie DJ, Gold MJ, To N, et al
    Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.
    Aliment Pharmacol Ther. 2017 Jan 20. doi: 10.1111/apt.13949.
    PubMed     Text format     Abstract available


  21. WHITEHEAD WE, Duffy K, Sharpe J, Nabata T, et al
    Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:14-26.
    PubMed     Text format     Abstract available


    November 2016
  22. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Text format     Abstract available


  23. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Text format     Abstract available


  24. XU XJ, Zhang YL, Liu L, Pan L, et al
    Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13848.
    PubMed     Text format     Abstract available


    October 2016
  25. PETERS SL, Yao CK, Philpott H, Yelland GW, et al
    Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? Authors' reply.
    Aliment Pharmacol Ther. 2016;44:902-3.
    PubMed     Text format    


  26. LOVDAHL J, Storsrud S, Tornblom H
    Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome?
    Aliment Pharmacol Ther. 2016;44:901-2.
    PubMed     Text format    


    September 2016
  27. CHANG L, Chey WD, Drossman D, Losch-Beridon T, et al
    Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2016 Sep 27. doi: 10.1111/apt.13807.
    PubMed     Text format     Abstract available


    August 2016
  28. BLAKE MR, Raker JM, Whelan K
    Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Aug 5. doi: 10.1111/apt.13746.
    PubMed     Text format     Abstract available


  29. DIEDEREN K, Hoekman DR, Benninga MA
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:309-10.
    PubMed     Text format    


  30. DAI C, Jiang M, Sun MJ
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:308-9.
    PubMed     Text format    


    July 2016
  31. KOLOSKI NA, Jones M, Talley NJ
    Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study.
    Aliment Pharmacol Ther. 2016 Jul 22. doi: 10.1111/apt.13738.
    PubMed     Text format     Abstract available


  32. WADHWA A, Al Nahhas MF, Dierkhising RA, Patel R, et al
    High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.
    Aliment Pharmacol Ther. 2016 Jul 22. doi: 10.1111/apt.13737.
    PubMed     Text format     Abstract available


  33. LAATIKAINEN R, Koskenpato J, Hongisto SM, Loponen J, et al
    Randomised clinical trial: low-FODMAP rye bread vs. regular rye bread to relieve the symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Jul 15. doi: 10.1111/apt.13726.
    PubMed     Text format     Abstract available


  34. PETERS SL, Yao CK, Philpott H, Yelland GW, et al
    Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Jul 11. doi: 10.1111/apt.13706.
    PubMed     Text format     Abstract available


    May 2016
  35. PATEL A, Hasak S, Cassell B, Ciorba MA, et al
    Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 May 30. doi: 10.1111/apt.13677.
    PubMed     Text format     Abstract available


  36. BARANSKA A, Mujagic Z, Smolinska A, Dallinga JW, et al
    Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.
    Aliment Pharmacol Ther. 2016 May 2. doi: 10.1111/apt.13654.
    PubMed     Text format     Abstract available


    April 2016
  37. DIEDEREN K, Hoekman DR, Hummel TZ, de Meij TG, et al
    The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Aliment Pharmacol Ther. 2016 Apr 25. doi: 10.1111/apt.13636.
    PubMed     Text format     Abstract available


    March 2016
  38. MUJAGIC Z, Keszthelyi D, Thijssen AY, Jonkers DM, et al
    Editorial: serotonin and irritable bowel syndrome - reconciling pharmacological effects with basic biology; authors' reply.
    Aliment Pharmacol Ther. 2016;43:646-7.
    PubMed     Text format    


  39. QUIGLEY EM
    Editorial: serotonin and irritable bowel syndrome - reconciling pharmacological effects with basic biology.
    Aliment Pharmacol Ther. 2016;43:644-6.
    PubMed     Text format    


    February 2016
  40. GUAGNOZZI D, Arias A, Lucendo AJ
    Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders.
    Aliment Pharmacol Ther. 2016 Feb 24. doi: 10.1111/apt.13573.
    PubMed     Text format     Abstract available


    January 2016
  41. HUNGIN AP, Paxman L, Koenig K, Dalrymple J, et al
    Prevalence, symptom patterns and management of episodic diarrhoea in the community: a population-based survey in 11 countries.
    Aliment Pharmacol Ther. 2016 Jan 8. doi: 10.1111/apt.13513.
    PubMed     Text format     Abstract available


  42. PIMENTEL M
    Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:37-49.
    PubMed     Text format     Abstract available


  43. DUPONT HL
    Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:1-2.
    PubMed     Text format     Abstract available


    December 2015
  44. CHUMPITAZI BP, Shulman RJ
    Letter: avoid FODMAPs or follow simple tips--authors' reply.
    Aliment Pharmacol Ther. 2015;42.
    PubMed     Text format    


  45. MENNINI M, Ferrari F
    Letter: avoid FODMAPs or follow simple tips?
    Aliment Pharmacol Ther. 2015;42.
    PubMed     Text format    


    November 2015
  46. GOTTLIEB K, Wacher V, Sliman J, Pimentel M, et al
    Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
    Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13469.
    PubMed     Text format     Abstract available


  47. THIJSSEN AY, Mujagic Z, Jonkers DM, Ludidi S, et al
    Alterations in serotonin metabolism in the irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Nov 5. doi: 10.1111/apt.13459.
    PubMed     Text format     Abstract available


  48. YAO CK, Muir JG, Gibson PR
    Review article: insights into colonic protein fermentation, its modulation and potential health implications.
    Aliment Pharmacol Ther. 2015 Nov 2. doi: 10.1111/apt.13456.
    PubMed     Text format     Abstract available


    September 2015
  49. RANGEL I, Sundin J, Fuentes S, Repsilber D, et al
    The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects.
    Aliment Pharmacol Ther. 2015 Sep 17. doi: 10.1111/apt.13399.
    PubMed     Text format     Abstract available


    August 2015
  50. MUJAGIC Z, Keszthelyi D, Aziz Q, Reinisch W, et al
    Systematic review: instruments to assess abdominal pain in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Aug 20. doi: 10.1111/apt.13378.
    PubMed     Text format     Abstract available


  51. WHELAN K
    Editorial: fibre and FODMAPs in constipation and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015;42:383-4.
    PubMed     Text format    


    June 2015
  52. CHUMPITAZI BP, Cope JL, Hollister EB, Tsai CM, et al
    Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Jun 24. doi: 10.1111/apt.13286.
    PubMed     Text format     Abstract available


  53. SOOD R, Gracie DJ, Law GR, Ford AC, et al
    Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers.
    Aliment Pharmacol Ther. 2015 Jun 15. doi: 10.1111/apt.13283.
    PubMed     Text format     Abstract available


  54. MILLER V, Carruthers H, Morris J, Hasan SS, et al
    Letter: efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome - authors' reply.
    Aliment Pharmacol Ther. 2015;41:1223-4.
    PubMed     Text format    


  55. DUBE S, Ford AC
    Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015;41:1222-3.
    PubMed     Text format    


  56. TALLEY NJ, Koloski NA, Jones MP
    Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome - possible and important? - Authors' reply.
    Aliment Pharmacol Ther. 2015;41:1300.
    PubMed     Text format    


  57. QUIGLEY EM
    Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome - possible and important?
    Aliment Pharmacol Ther. 2015;41:1299.
    PubMed     Text format    


  58. PETERS SL, Gibson PR
    Editorial: a new shift in the paradigm of treatment for the irritable bowel syndrome?
    Aliment Pharmacol Ther. 2015;41:1296.
    PubMed     Text format    


    May 2015
  59. CASEN C, Vebo HC, Sekelja M, Hegge FT, et al
    Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD.
    Aliment Pharmacol Ther. 2015 May 14. doi: 10.1111/apt.13236.
    PubMed     Text format     Abstract available


    April 2015
  60. SLATTERY SA, Niaz O, Aziz Q, Ford AC, et al
    Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2015 Apr 27. doi: 10.1111/apt.13227.
    PubMed     Text format     Abstract available


  61. RAO SS, Yu S, Fedewa A
    Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Apr 22. doi: 10.1111/apt.13167.
    PubMed     Text format     Abstract available


  62. SCHWILLE-KIUNTKE J, Mazurak N, Enck P
    Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea.
    Aliment Pharmacol Ther. 2015 Apr 13. doi: 10.1111/apt.13199.
    PubMed     Text format     Abstract available


  63. PETERS SL, Muir JG, Gibson PR
    Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Apr 10. doi: 10.1111/apt.13202.
    PubMed     Text format     Abstract available


  64. DAI C, Jiang M, Sun MJ
    Letter: irritable bowel syndrome is significantly associated with somatisation.
    Aliment Pharmacol Ther. 2015;41:791.
    PubMed     Text format    


  65. PATEL P, Ford AC
    Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply.
    Aliment Pharmacol Ther. 2015;41:791-2.
    PubMed     Text format    


  66. CAMILLERI M
    Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea - author's reply.
    Aliment Pharmacol Ther. 2015;41:697.
    PubMed     Text format    


  67. WALTERS JR, Appleby RN
    Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea.
    Aliment Pharmacol Ther. 2015;41:696-7.
    PubMed     Text format    


    March 2015
  68. MOLINA-INFANTE J, Santolaria S, Sanders DS, Fernandez-Banares F, et al
    Systematic review: noncoeliac gluten sensitivity.
    Aliment Pharmacol Ther. 2015 Mar 6. doi: 10.1111/apt.13155.
    PubMed     Text format     Abstract available


  69. KOLOSKI NA, Jones M, Young M, Talley NJ, et al
    Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study.
    Aliment Pharmacol Ther. 2015 Mar 4. doi: 10.1111/apt.13149.
    PubMed     Text format     Abstract available


  70. MILLER V, Carruthers HR, Morris J, Hasan SS, et al
    Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients.
    Aliment Pharmacol Ther. 2015 Mar 4. doi: 10.1111/apt.13145.
    PubMed     Text format     Abstract available


  71. LE PLUART D, Sabate JM, Bouchoucha M, Hercberg S, et al
    Functional gastrointestinal disorders in 35 447 adults and their association with body mass index.
    Aliment Pharmacol Ther. 2015 Mar 1. doi: 10.1111/apt.13143.
    PubMed     Text format     Abstract available


    January 2015
  72. CAMILLERI M, Acosta A, Busciglio I, Boldingh A, et al
    Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Jan 16. doi: 10.1111/apt.13065.
    PubMed     Text format     Abstract available


  73. PATEL P, Bercik P, Morgan DG, Bolino C, et al
    Irritable bowel syndrome is significantly associated with somatisation in 804 patients, which may drive bloating.
    Aliment Pharmacol Ther. 2015 Jan 14. doi: 10.1111/apt.13074.
    PubMed     Text format     Abstract available


  74. QUIGLEY EM
    Editorial: allergy and recurrent abdominal pain of childhood/irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015;41:229.
    PubMed     Text format    


    December 2014
  75. SUNDIN J, Rangel I, Fuentes S, Heikamp-de Jong I, et al
    Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress.
    Aliment Pharmacol Ther. 2014 Dec 18. doi: 10.1111/apt.13055.
    PubMed     Text format     Abstract available


    November 2014
  76. SPILLER R
    Editorial: abnormal permeability and altered mucosal serotonin metabolism in the irritable bowel syndrome - is there a link?
    Aliment Pharmacol Ther. 2014;40:1116-1118.
    PubMed     Text format    


  77. JONES MP, Walker MM, Ford AC, Talley NJ, et al
    Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care--authors' reply.
    Aliment Pharmacol Ther. 2014;40:1244-5.
    PubMed     Text format    


  78. WU JC
    Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care.
    Aliment Pharmacol Ther. 2014;40:1244.
    PubMed     Text format    


    October 2014
  79. FUTAGAMI S, Itoh T, Sakamoto C
    Systematic review: post-infectious functional dyspepsia.
    Aliment Pharmacol Ther. 2014 Oct 27. doi: 10.1111/apt.13006.
    PubMed     Text format     Abstract available


  80. TURNBULL JL, Adams HN, Gorard DA
    Review article: the diagnosis and management of food allergy and food intolerances.
    Aliment Pharmacol Ther. 2014 Oct 14. doi: 10.1111/apt.12984.
    PubMed     Text format     Abstract available


    September 2014
  81. HUNGIN AP, Molloy-Bland M, Claes R, Heidelbaugh J, et al
    Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - A Rome Foundation Working Team Report.
    Aliment Pharmacol Ther. 2014 Sep 17. doi: 10.1111/apt.12957.
    PubMed     Text format     Abstract available


  82. CANAVAN C, West J, Card T
    Review article: the economic impact of the irritable bowel syndrome.
    Aliment Pharmacol Ther. 2014 Sep 9. doi: 10.1111/apt.12938.
    PubMed     Text format     Abstract available


    August 2014
  83. MARAFINI I, Di Sabatino A, Zorzi F, Monteleone I, et al
    Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies.
    Aliment Pharmacol Ther. 2014 Aug 11. doi: 10.1111/apt.12920.
    PubMed     Text format     Abstract available


  84. FORD AC, Talley NJ, Walker MM, Jones MP, et al
    Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23 471 primary care patients.
    Aliment Pharmacol Ther. 2014 Aug 8. doi: 10.1111/apt.12903.
    PubMed     Text format     Abstract available


  85. MORAN C, Shanahan F
    Editorial: probiotics and IBS - where are we now?
    Aliment Pharmacol Ther. 2014;40:318.
    PubMed     Text format    


  86. MUJAGIC Z, Ludidi S, Keszthelyi D, Hesselink MA, et al
    Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders.
    Aliment Pharmacol Ther. 2014;40:288-97.
    PubMed     Text format     Abstract available


    July 2014
  87. SCHOENFELD P, Pimentel M
    Editorial: safety and tolerability of rifaximin for IBS - more information is required; authors' reply.
    Aliment Pharmacol Ther. 2014;40:209.
    PubMed     Text format    


  88. CAI ST, Yang YS
    Editorial: safety and tolerability of rifaximin for IBS - more information is required.
    Aliment Pharmacol Ther. 2014;40:208.
    PubMed     Text format    


  89. PETERS SL, Biesiekierski JR, Yelland GW, Muir JG, et al
    Editorial: Noncoeliac gluten sensitivity--a disease of the mind or gut? Authors' reply.
    Aliment Pharmacol Ther. 2014;40:114-5.
    PubMed     Text format    


  90. AZIZ I, Hadjivassiliou M, Sanders DS
    Editorial: Noncoeliac gluten sensitivity--a disease of the mind or gut?
    Aliment Pharmacol Ther. 2014;40:113-4.
    PubMed     Text format    


    June 2014
  91. JONES MP, Walker MM, Ford AC, Talley NJ, et al
    The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care.
    Aliment Pharmacol Ther. 2014 Jun 25. doi: 10.1111/apt.12846.
    PubMed     Text format     Abstract available


  92. KESZTHELYI D, Troost FJ, Jonkers DM, van Eijk HM, et al
    Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2014 Jun 18. doi: 10.1111/apt.12842.
    PubMed     Text format     Abstract available


  93. WILLIAMS VS, Nelson LM, Fehnel SE, MacDougall J, et al
    Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2014 Jun 18. doi: 10.1111/apt.12830.
    PubMed     Text format     Abstract available


    May 2014
  94. SISSON G, Ayis S, Sherwood RA, Bjarnason I, et al
    Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12 week double-blind study.
    Aliment Pharmacol Ther. 2014 May 11. doi: 10.1111/apt.12787.
    PubMed     Text format     Abstract available


    April 2014
  95. GOMOLLON F, Chowers Y, Danese S, Dignass A, et al
    Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.
    Aliment Pharmacol Ther. 2014;39:743-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: